Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03436199 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment
A Phase 3 study, sponsored by Adamas Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 558
- Enrollment target
NCT03436199 is a Phase 3 study that has completed, run by Adamas Pharmaceuticals. The registered enrollment target is 558 participants.
The verdict
NCT03436199, a Phase 3 study, has completed, sponsored by Adamas Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 558 participants
- Enrollment target
Study Summary
This study assessed the efficacy and safety of ADS-5102 (at daily doses of 137 mg or 274 mg) compared with placebo in MS patients with walking impairment.
Interventions
- OTHER Placebo
- DRUG ADS-5102, 274 mg
- DRUG ADS-5102, 137 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 558 participants |
| Start Date | 2018-03-29 |
| Est. Completion | 2019-12-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03436199
The ClinicalTrials.gov registry entry for NCT03436199 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 558 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adamas Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03436199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03436199 about?
NCT03436199 is a clinical study titled "Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment". This study assessed the efficacy and safety of ADS-5102 (at daily doses of 137 mg or 274 mg) compared with placebo in MS patients with walking impairment.
What is the current status of trial NCT03436199?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 558 participants. The study started on 2018-03-29. Estimated completion is 2019-12-10.
What interventions are being tested in trial NCT03436199?
The interventions under investigation include: Placebo (OTHER), ADS-5102, 274 mg (DRUG), ADS-5102, 137 mg (DRUG).
Who is sponsoring clinical trial NCT03436199?
This trial is sponsored by Adamas Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.